查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
北美獸醫腫瘤市場規模、佔有率、趨勢分析報告：按動物類型、治療方法、癌症類型、國家、細分市場預測，2023-2033 年
市場調查報告書
商品編碼
1375929

北美獸醫腫瘤市場規模、佔有率、趨勢分析報告：按動物類型、治療方法、癌症類型、國家、細分市場預測，2023-2033 年

North America Veterinary Oncology Market Size, Share & Trends Analysis Report By Animal Type (Canine, Feline), By Therapy (Radiotherapy, Surgery), By Cancer Type, By Country, And Segment Forecasts, 2023 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

北美獸醫腫瘤市場成長與趨勢

Grand View Research, Inc. 的最新報告顯示，到 2033 年，北美獸醫腫瘤市場規模預計將達到 14.6 億美元。

預計2023年至2033年該市場將以10.57%的年複合成長率成長。該市場的推動因素包括寵物癌症盛行率的上升、調查各種癌症治療的安全性和有效性的獸醫臨床試驗的數量以及寵物保險普及的上升。此外，針對伴侶動物癌症標靶治療的研究和開發的策略性舉措不斷增加正在推動市場成長。例如，2023 年 7 月，Ardent Animal Health 與 FidoCure 合作，利用後者的基因組測試和精準醫療平台，擴大動物健康領域腫瘤學創新的機會。

在 COVID-19 期間，由於面臨多項挑戰，市場成長緩慢。這場流行病影響了獸醫癌症研究和開發工作以及關鍵寵物藥品的後勤供應。獲得獸醫護理的機會也受到限制。根據世界動物健康協會2020年報告，對寵物飼主的一項調查發現，在許多國家，獸醫服務因寵物獸醫護理的延誤或遺漏而受到阻礙，據說確實有。但這場大流行也加速了數位科技的採用，以加強護理。 2020 年 3 月，PetCure Oncology 升級了其遠距醫療選項，讓寵物家庭和轉診獸醫與公司經過董事會認證的放射腫瘤學家遠端連接。

由於有多個大大小小的參與企業，市場分散且競爭激烈。參與企業正在積極制定策略性舉措以獲取市場佔有率。例如，2022年1月，Decra從Anivive Lifesciences手中收購了Labeldia-CA1（Vergynexol片劑）在美國的銷售、行銷和支援權。 2022年6月，勃林格殷格翰國際股份有限公司與生物製藥公司CarthroniX建立研究夥伴關係，開發犬隻癌症領域的小分子療法。 2023 年 4 月，Torigen Pharmaceuticals 將與獸醫管理集團 (VMG) 合作，向 VMG 的 2,000 多家會員診所網路提供該公司的實驗性自製配方產品和服務。

北美獸醫腫瘤學市場報告亮點

  • 按動物類型分類，2022 年犬類細分市場佔據主導地位，佔收益佔有率超過 85%。同時，貓科動物預計在預測期內將以超過 12% 的年複合成長率成長最快。這是由夥伴關係和研究合作的增加所推動的，以進一步開發可靠的獸醫癌症治療並將其推向市場。例如，2022 年 10 月，Ardent Animal Health 完成了一項用於治療狗癌症的新型檢查點抑制劑的許可協議。
  • 從治療方法來看，手術領域佔據市場主導地位，2022年收益佔有率將超過35%。預計免疫治療領域在預測期內將以 12% 的最快年複合成長率成長。
  • 按癌症類型分類，皮膚癌領域佔據市場主導地位，2022 年收益佔有率將超過 38%。預計其他細分市場在預測期內將以超過 11% 的年複合成長率成長最快。
  • 按國家/地區分類，美國在 2022 年佔據市場最大的收益佔有率，而加拿大預計在預測期內年複合成長率將超過 13%。美國的成長得益於主要參與企業的存在以及市場參與企業的策略性舉措。 2023 年 4 月，Torigen Pharmaceuticals 在美國康乃狄克州法明頓開設了新的生產設施和總公司。

目錄

第1章 調查方法和範圍

第2章 執行摘要

第3章 北美獸醫腫瘤市場產業展望

  • 市場體系展望
  • 北美獸醫腫瘤學市場動態
  • 北美獸醫腫瘤市場：波特五力分析
  • 北美獸醫腫瘤市場：PESTEL 分析
  • 法規狀況
  • 贖回形勢
  • COVID-19 影響分析
  • 從使用者觀點分析
  • 2018-2030年美國獸醫服務機構預計數量
  • 2022 年按物種和國家估計的動物數量
  • 癌症治療的估計平均費用
  • 預計腫瘤切除手術數量
  • 獲得認證的獸醫腫瘤學專家的估計數量

第4章 2018-2033 年動物類型、估計和趨勢分析（百萬美元）

  • 按動物類型分類的北美獸醫腫瘤學市場：要點
  • 2022 年和 2033 年動物類型變化分析和市場佔有率
  • 依動物類型
  • 犬科動物
    • 2018-2033 年犬類市場估計與預測
  • 貓科動物
    • 2018-2033 年貓科動物市場估計與預測
  • 馬
    • 馬匹市場估計與預測，2018-2033

第5章 2018-2033 年治療估計與趨勢分析（百萬美元）

  • 北美獸醫腫瘤治療方法市場：要點
  • 2022年和2033年處理變化分析和市場佔有率
  • 依治療方法
    • 北美放射治療市場，按類型，2018-2033
  • 放射線治療
    • 2018-2033 年放射治療市場估計與預測
    • 立體定位放射治療
    • 常規放射治療
  • 外科手術
    • 2018-2033 年手術市場估計與預測
  • 化療
    • 2018-2033 年化療市場估計與預測
  • 免疫療法
    • 2018-2033 年免疫治療市場估計與預測
  • 其他治療方法
    • 2018-2033 年其他治療藥物市場估計與預測

第6章 癌症類型、估計和趨勢分析，2018-2033 年（百萬美元）

  • 按癌症類型分類的北美獸醫腫瘤學市場：要點
  • 2022 年和 2033 年癌症類型變化分析和市場佔有率
  • 按癌症類型
  • 皮膚癌
    • 2018-2033 年皮膚癌市場估計與預測
  • 淋巴瘤
    • 2018-2033 年淋巴瘤市場估計與預測
  • 肉瘤
    • 2018-2033 年肉瘤市場估計與預測
  • 其他
    • 2018-2033 年其他市場估計與預測

第7章 2018-2033 年區域估算與趨勢分析（百萬美元）

  • 區域展望
  • 北美洲
    • 北美獸醫腫瘤學市場估計與預測，2018-2033
    • 美國
    • 加拿大

第8章 競爭形勢

  • 市場參與企業分類
  • 2022 年企業市場分析（熱圖分析）
  • 市場領導與創新者
  • 主要公司簡介
  • 策略規劃
    • 核准授權
    • 併購
    • 夥伴關係與協作
    • 產品/服務的推出/擴展
    • 研究與開發夥伴關係
    • 其他
  • 其他主要市場參與企業名單
Product Code: GVR-4-68040-138-7

North America Veterinary Oncology Market Growth & Trends:

The North America veterinary oncology market size is expected to reach USD 1.46 billion by 2033, according to a new report by Grand View Research, Inc.. The market is projected to grow at a CAGR of 10.57% from 2023 to 2033. The market is driven by the rising incidence of cancer in pets, the number of veterinary clinical trials investigating the safety and effectiveness of various oncologic therapies, and the increasing penetration of pet insurance. Moreover, increasing strategic initiatives for R&D of targeted therapies for cancer in companion animals is boosting market growth. For instance, in July 2023, Ardent Animal Health partnered with FidoCure to expand access to oncology innovation in veterinary medicine by leveraging the latter's genomic testing and precision medicine platform.

During COVID-19, the market witnessed dampened growth owing to several challenges. The pandemic impacted veterinary cancer research & development efforts and the logistics supply of crucial pet pharmaceuticals. It also limited access to veterinary care. According to the Global Animal Health Association's 2020 report, pet owners in a study said that in many countries, veterinarian services were hampered by delayed or skipped care for pets. The pandemic, however, also accelerated the adoption of digital technologies to enhance care. In March 2020, PetCure Oncology upgraded its Telehealth options to enable pet families and referring veterinarians to remotely connect with its board-certified radiation oncologists.

The market is fragmented and competitive due to the presence of several small-to-large market players. Players are actively involved in deploying strategic initiatives to gain market share. For instance, in January 2022, Dechra acquired the rights to sell, market, and support Laverdia-CA1 (verdinexor tablets) in the U.S. from Anivive Lifesciences, Inc. In June 2022, Boehringer Ingelheim International GmbH entered into a research partnership with CarthroniX, a biopharma company, to develop small molecule therapeutics in canine oncology. In April 2023, Torigen Pharmaceuticals partnered with Veterinary Management Groups (VMG) to provide their experimental autologous prescription products and services to the latter's more than 2,000 member clinics network.

North America Veterinary Oncology Market Report Highlights:

  • Based on animal type, the canine segment dominated the market in 2022 with a revenue share of over 85%. The feline segment, on the other hand, is projected to grow at the fastest CAGR of over 12% over the forecast period. This is attributed to the increasing partnerships and collaborations to further the development and launch of reliable veterinary cancer therapies. In October 2022, Ardent Animal Health, for example, completed a license agreement for a novel checkpoint inhibitor for canine cancer treatment
  • In terms of therapy, the surgery segment dominated the market in 2022 with a revenue share of over 35%. The immunotherapy segment is projected to grow at the fastest CAGR of 12% over the forecast period
  • Based on cancer type, the skin cancers segment dominated the market in 2022 with a revenue share of over 38%. The others segment is projected to grow at the fastest CAGR of over 11% over the forecast period
  • Based on country, the U.S. held the largest revenue share in the market in 2022, while Canada is anticipated to grow at a CAGR of over 13% over the forecast period. The growth in the U.S. is attributed to the presence of key players and strategic initiatives by market players. In April 2023, Torigen Pharmaceuticals opened a new production facility and headquarters in Farmington, Connecticut, U.S.

Table of Contents

Chapter 1 Methodology And Scope

  • 1.1 Market Segmentation And Scope
    • 1.1.1 Report Scope & Assumptions
    • 1.1.2 Country Scope And Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database
    • 1.3.2 Gvr's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
  • 1.4 Information/Data Analysis
    • 1.4.1 Information Analysis
  • 1.5 Market Formulation & Visualization
  • 1.6 Data Validation & Publishing
  • 1.7 Model Details
    • 1.7.1 Approach 1: Volume X Price Analysis
      • 1.7.1.1 Bottom-Up Market Estimation
      • 1.7.1.2 Top-Down Market Estimation
    • 1.7.2 Approach 2: Commodity Flow Analysis
    • 1.7.3 Global Market: Cagr Calculation
  • 1.8 List Of Secondary Sources

Chapter 2 Executive Summary

  • 2.1 Market Snapshot
  • 2.2 Animal Type & Therapy Segment Snapshot
  • 2.3 Cancer Type Segment Snapshot
  • 2.4 Competitive Landscape Snapshot

Chapter 3 North America Veterinary Oncology Market Industry Outlook

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent Market Analysis
    • 3.1.2 Ancillary Market Analysis
  • 3.2 North America Veterinary Oncology Market Dynamics
    • 3.2.1 Market Driver Impact Analysis
      • 3.2.1.1 Increasing Prevalence Of Cancer In Pets
      • 3.2.1.2 Increasing R&D In Pet Cancer Therapy
      • 3.2.1.3 Growing Focus On Animal Safety
      • 3.2.1.4 Growing Uptake Of Pet Insurance
      • 3.2.1.5 Technological Advancements In Pet Cancer Treatment
      • 3.2.1.6 Increase In Pet Population
    • 3.2.2 Market Restraint Impact Analysis
      • 3.2.2.1 High Cost Of Treatment
      • 3.2.2.2 Adverse Effects Associated With Therapies
      • 3.2.2.3 Limited Clinical Evidence
    • 3.2.3 Market Opportunity Analysis
    • 3.2.4 Market Challenge Analysis
  • 3.3 North America Veterinary Oncology Market: Porter's 5 Forces Analysis
    • 3.3.1 Bargaining Power Of Buyers
    • 3.3.2 Bargaining Power Of Suppliers
    • 3.3.3 Threat Of New Entrants
    • 3.3.4 Threat Of Substitutes
    • 3.3.5 Competitive Rivalry
  • 3.4 North America Veterinary Oncology Market: Pestel Analysis
    • 3.4.1 Political & Legal Landscape
    • 3.4.2 Economic Landscape
    • 3.4.3 Technological Landscape
    • 3.4.4 Social Landscape
    • 3.4.5 Environmental Landscape
  • 3.5 Regulatory Landscape
  • 3.6 Reimbursement Landscape
  • 3.7 Covid-19 Impact Analysis
  • 3.8 User Perspective Analysis
  • 3.9 Estimated Number Of Veterinary Service Establishments In The U.S., 2018 To 2030
  • 3.10 Estimated Animal Population By Species And By Country, 2022
  • 3.11 Estimated Average Cost Of Cancer Treatment
  • 3.12 Estimated Number Of Tumor Removal Procedures
  • 3.13 Estimated Number Of Certified Veterinary Oncologists

Chapter 4 Animal Type Estimates & Trend Analysis, 2018 - 2033 (USD Million)

  • 4.1 North America Veterinary Oncology Market By Animal Type: Key Takeaways
  • 4.2 Animal Type Movement Analysis & Market Share, 2022 & 2033
  • 4.3 North America Veterinary Oncology Market Estimates & Forecast, By Animal Type (USD Million)
  • 4.4 Canine
    • 4.4.1 Canine Market Estimates And Forecasts, 2018 - 2033 (USD Million)
  • 4.5 Feline
    • 4.5.1 Feline Market Estimates And Forecasts, 2018 - 2033 (USD Million)
  • 4.6 Equine
    • 4.6.1 Equine Market Estimates And Forecasts, 2018 - 2033 (USD Million)

Chapter 5 Therapy Estimates & Trend Analysis, 2018 - 2033 (USD Million)

  • 5.1 North America Veterinary Oncology Market By Therapy: Key Takeaways
  • 5.2 Therapy Movement Analysis & Market Share, 2022 & 2033
  • 5.3 North America Veterinary Oncology Market Estimates & Forecast, By Therapy (USD Million)
    • 5.3.1. North America radiotherapy Market, By Type, 2018 - 2033 (USD Million)
      • 5.3.1.1. North America Stereotactic Radiation Therapy Market, By Type, 2018 - 2033 (USD Million)
  • 5.4 Radiotherapy
    • 5.4.1 Radiotherapy Market Estimates And Forecasts, 2018 - 2033 (USD Million)
    • 5.4.2 Stereotactic Radiation Therapy
      • 5.4.2.1 Stereotactic Radiation Therapy Market Estimates And Forecasts, 2018 - 2033 (USD Million)
      • 5.4.2.2 Linac
      • 5.4.2.2.1 Linac Market Estimates And Forecasts, 2018 - 2033 (USD Million)
      • 5.4.2.3 Others
      • 5.4.2.3.1 Others Market Estimates And Forecasts, 2018 - 2033 (USD Million)
    • 5.4.3 Conventional Radiation Therapy
      • 5.4.3.1 Conventional Radiation Therapy Market Estimates And Forecasts, 2018 - 2033 (USD Million)
  • 5.5 Surgery
    • 5.5.1 Surgery Market Estimates And Forecasts, 2018 - 2033 (USD Million)
  • 5.6 Chemotherapy
    • 5.6.1 Chemotherapy Market Estimates And Forecasts, 2018 - 2033 (USD Million)
  • 5.7 Immunotherapy
    • 5.7.1 Immunotherapy Market Estimates And Forecasts, 2018 - 2033 (USD Million)
  • 5.8 Other Therapies
    • 5.8.1 Other Therapies Market Estimates And Forecasts, 2018 - 2033 (USD Million)

Chapter 6 Cancer Type Estimates & Trend Analysis, 2018 - 2033 (USD Million)

  • 6.1 North America Veterinary Oncology Market By Cancer Type: Key Takeaways
  • 6.2 Cancer Type Movement Analysis & Market Share, 2022 & 2033
  • 6.3 North America Veterinary Oncology Market Estimates & Forecast, By Cancer Type (USD Million)
  • 6.4 Skin Cancers
    • 6.4.1 Skin Cancers Market Estimates And Forecasts, 2018 - 2033 (USD Million)
  • 6.5 Lymphomas
    • 6.5.1 Lymphomas Market Estimates And Forecasts, 2018 - 2033 (USD Million)
  • 6.6 Sarcomas
    • 6.6.1 Sarcomas Market Estimates And Forecasts, 2018 - 2033 (USD Million)
  • 6.7 Others
    • 6.7.1 Others Market Estimates And Forecasts, 2018 - 2033 (USD Million)

Chapter 7 Regional Estimates & Trend Analysis, 2018 - 2033 (USD Million)

  • 7.1 Regional Outlook
  • 7.2 North America
    • 7.2.1 North America Veterinary Oncology Market Estimates And Forecasts, 2018 - 2033 (USD Million)
    • 7.2.2 U.S.
      • 7.2.2.1 U.S. Veterinary Oncology Market Estimates And Forecasts, 2018 - 2033 (USD Million)
    • 7.2.3 Canada
      • 7.2.3.1 Canada Veterinary Oncology Market Estimates And Forecasts, 2018 - 2033 (USD Million)

Chapter 8 Competitive Landscape

  • 8.1 Market Participant Categorization
  • 8.2 Company Market Position Analysis, 2022, (Heat Map Analysis)
  • 8.3 Market Leaders & Innovators
  • 8.4 Key Company Profiles
    • 8.4.1 Participants Overview
    • 8.4.2 Financial Performance
    • 8.4.3 Therapy Benchmarking
    • 8.4.4 Strategic Initiatives
      • 8.4.4.1 Boehringer Ingelheim International Gmbh
      • 8.4.4.2 Elanco Animal Health
      • 8.4.4.3 Zoetis Services Llc
      • 8.4.4.4 Elekta Ab
      • 8.4.4.5 Petcure Oncology
      • 8.4.4.6 Accuray Incorporated
      • 8.4.4.7 Varian Medical Systems, Inc. (Parent Company: Siemens Healthineers)
      • 8.4.4.8 Virbac
      • 8.4.4.9 Torigen Pharmaceuticals Inc.
      • 8.4.4.10 Dechra Pharmaceuticals Plc
      • 8.4.4.11 Novavive Inc.
      • 8.4.4.12 Ardent Animal Health, Llc (A Breakthru Company)
  • 8.5 Strategy Mapping
    • 8.5.1 Approvals & Clearances
    • 8.5.2 Mergers & Acquisitions
    • 8.5.3 Partnerships & Collaborations
    • 8.5.4 Product/ Service Launches/Expansions
    • 8.5.5 R&D Partnerships
    • 8.5.6 Others
  • 8.6 List Of Other Key Market Players

List of Tables

  • Table 1 List of secondary sources
  • Table 2 North America Veterinary Oncology market, by Country, 2018 - 2033 (USD Million)
  • Table 3 North America Veterinary Oncology market, by Animal Type, 2018 - 2033 (USD Million)
  • Table 4 North America Veterinary Oncology market, by Therapy, 2018 - 2033 (USD Million)
  • Table 5 North America Radiotherapy Market, by Type, 2018 - 2033 (USD Million)
  • Table 6 North America Stereotactic Radiation Therapy Market, by Type, 2018 - 2033 (USD Million)
  • Table 7 North America Veterinary Oncology Market, by Cancer Type, 2018 - 2033 (USD Million)
  • Table 8 US Veterinary Oncology market, by Animal Type, 2018 - 2033 (USD Million)
  • Table 9 US Veterinary Oncology market, by Therapy, 2018 - 2033 (USD Million)
  • Table 10 US Radiotherapy Market, by Type, 2018 - 2033 (USD Million)
  • Table 11 US Stereotactic Radiation Therapy Market, by Type, 2018 - 2033 (USD Million)
  • Table 12 US Veterinary Oncology Market, by Cancer Type, 2018 - 2033 (USD Million)
  • Table 13 Canada Veterinary Oncology market, by Animal Type, 2018 - 2033 (USD Million)
  • Table 14 Canada Veterinary Oncology market, by Therapy, 2018 - 2033 (USD Million)
  • Table 15 Canada Radiotherapy Market, by Type, 2018 - 2033 (USD Million)
  • Table 16 Canada Stereotactic Radiation Therapy Market, by Type, 2018 - 2033 (USD Million)
  • Table 17 Canada Veterinary Oncology Market, by Cancer Type, 2018 - 2033 (USD Million)

List of Figures

  • Fig. 1 North America Veterinary Oncology market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Data Analysis Models
  • Fig. 6 Market Formulation And Validation
  • Fig. 7 Data Validating & Publishing
  • Fig. 8 Volume x Price Analysis
  • Fig. 9 Commodity flow analysis
  • Fig. 10 Market snapshot
  • Fig. 11 Segment snapshot
  • Fig. 12 Competitive landscape snapshot
  • Fig. 13 Parent market outlook, 2022
  • Fig. 14 Ancillary market outlook, 2022
  • Fig. 15 North America Veterinary Oncology market: PESTEL analysis
  • Fig. 16 Estimated Number of Veterinary Service Establishments in the U.S., 2018 to 2030
  • Fig. 17 North America Veterinary Oncology market by Animal Type: Key takeaways
  • Fig. 18 North America Veterinary Oncology market by Animal Type, Market share, 2022 & 2033
  • Fig. 19 Canine market, 2018 - 2033 (USD Million)
  • Fig. 20 Feline market, 2018 - 2033 (USD Million)
  • Fig. 21 Equine market, 2018 - 2033 (USD Million)
  • Fig. 22 North America Veterinary Oncology market by Therapy: Key takeaways
  • Fig. 23 North America Veterinary Oncology market by Therapy, market share, 2022 & 2033
  • Fig. 24 Radiotherapy market, 2018 - 2033 (USD Million)
  • Fig. 25 Stereotactic Radiation Therapy market, 2018 - 2033 (USD Million)
  • Fig. 26 LINAC market, 2018 - 2033 (USD Million)
  • Fig. 27 Others market, 2018 - 2033 (USD Million)
  • Fig. 28 Conventional Radiation Therapy market, 2018 - 2033 (USD Million)
  • Fig. 29 Surgery market, 2018 - 2033 (USD Million)
  • Fig. 30 Chemotherapy market, 2018 - 2033 (USD Million)
  • Fig. 31 Immunotherapy market, 2018 - 2033 (USD Million)
  • Fig. 32 Other Therapies market, 2018 - 2033 (USD Million)
  • Fig. 33 North America Veterinary Oncology market by Cancer Type: Key takeaways
  • Fig. 34 North America Veterinary Oncology market by Cancer Type, market share, 2022 & 2033
  • Fig. 35 Skin Cancers market, 2018 - 2033 (USD Million)
  • Fig. 36 Lymphomas market, 2018 - 2033 (USD Million)
  • Fig. 37 Sarcomas market, 2018 - 2033 (USD Million)
  • Fig. 38 Others market, 2018 - 2033 (USD Million)
  • Fig. 39 Regional Marketplace: Key Takeaways
  • Fig. 40 North America Veterinary Oncology market estimates and forecasts, 2018 - 2033 (USD Million)
  • Fig. 41 U.S. Veterinary Oncology market estimates and forecasts, 2018 - 2033 (USD Million)
  • Fig. 42 Canada Veterinary Oncology market estimates and forecasts, 2018 - 2033 (USD Million)
  • Fig. 43 Market participant categorization
  • Fig. 44 Heat map analysis
  • Fig. 45 Key strategies deployed by market players